Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialopen access
- Authors
- Escudier, B[Escudier, B.]; Michaelson, MD[Michaelson, M. D.]; Motzer, RJ[Motzer, R. J.]; Hutson, TE[Hutson, T. E.]; Clark, JI[Clark, J. I.]; Lim, HY[Lim, H. Y.]; Porfiri, E[Porfiri, E.]; Zalewski, P[Zalewski, P.]; Kannourakis, G[Kannourakis, G.]; Staehler, M[Staehler, M.]; Tarazi, J[Tarazi, J.]; Rosbrook, B[Rosbrook, B.]; Cisar, L[Cisar, L.]; Hariharan, S[Hariharan, S.]; Kim, S[Kim, S.]; Rini, BI[Rini, B. I.]
- Issue Date
- 10-Jun-2014
- Publisher
- NATURE PUBLISHING GROUP
- Keywords
- Axitinib; Prior therapy; Renal cell carcinoma; Sorafenib; VEGF receptor inhibitor
- Citation
- BRITISH JOURNAL OF CANCER, v.110, no.12, pp.2821 - 2828
- Indexed
- SCIE
SCOPUS
- Journal Title
- BRITISH JOURNAL OF CANCER
- Volume
- 110
- Number
- 12
- Start Page
- 2821
- End Page
- 2828
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/52640
- DOI
- 10.1038/bjc.2014.244
- ISSN
- 0007-0920
- Abstract
- Background: In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines. Methods: In post hoc analyses, patients were grouped by objective response to prior therapy (yes vs no), prior therapy duration (< vs >= median), and tumour burden (baseline sum of the longest diameter < vs >= median). PFS and overall survival (OS), and safety by type and duration of prior therapy were evaluated. Results: Response to prior therapy did not influence outcome with second-line axitinib or sorafenib. PFS was significantly longer in axitinib-treated patients who received longer prior cytokine treatment and sorafenib-treated patients with smaller tumour burden following sunitinib. Overall survival with the second-line therapy was longer in patients who received longer duration of prior therapy, although not significant in the sunitinib-to-axitinib sequence subgroup; OS was also longer in patients with smaller tumour burden, but not significant in the cytokine-to-axitinib sequence subgroup. Safety profiles differed modestly by type and duration of prior therapy. Conclusions: AXIS data suggest that longer duration of the first-line therapy generally yields better outcome with the second-line therapy and that lack of response to first-line therapy does not preclude positive clinical outcomes with a second-line vascular endothelial growth factor-targeted agent in patients with advanced RCC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.